Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer's disease mouse model

Nat Commun. 2024 Sep 13;15(1):8024. doi: 10.1038/s41467-024-52301-w.

Abstract

The conditions supporting the generation of microglia-like cells in the central nervous system (CNS) after transplantation of hematopoietic stem/progenitor cells (HSPC) have been studied to advance the treatment of neurodegenerative disorders. Here, we explored the transplantation efficacy of different cell subsets and delivery routes with the goal of favoring the establishment of a stable and exclusive engraftment of HSPCs and their progeny in the CNS of female mice. In this setting, we show that the CNS environment drives the expansion, distribution and myeloid differentiation of the locally transplanted cells towards a microglia-like phenotype. Intra-CNS transplantation of HSPCs engineered to overexpress TREM2 decreased neuroinflammation, Aβ aggregation and improved memory in 5xFAD female mice. Our proof of concept study demonstrates the therapeutic potential of HSPC gene therapy for Alzheimer's disease.

MeSH terms

  • Alzheimer Disease* / genetics
  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / therapy
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Cell Differentiation
  • Disease Models, Animal*
  • Female
  • Genetic Therapy* / methods
  • Hematopoietic Stem Cell Transplantation* / methods
  • Hematopoietic Stem Cells* / metabolism
  • Humans
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic*
  • Microglia* / metabolism
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / metabolism

Substances

  • Trem2 protein, mouse
  • Receptors, Immunologic
  • Membrane Glycoproteins
  • Amyloid beta-Peptides